Nafcillin for Injection recalled nationwide for lack of sterility assurance
Sagent Pharmaceuticals is recalling Nafcillin for Injection, USP due to lack of assurance of sterility. Approximately 2.2 million vials distributed nationwide are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable antibiotic with lack of sterility assurance. While no illnesses or injuries have been reported, the hazard is inherent to unsterile injectable medications, and the source text does not document reported illness, making this a theoretical risk that qualifies as High per the rubric.
Plain-English summary
Sagent Pharmaceuticals is recalling Nafcillin for Injection, USP, 1 gram per vial (NDC 25021-139-10) due to lack of assurance of sterility. The recall affects three lots: NFG101 (expiration 1/31/2024), NFG102 (expiration 9/30/2024), and NFG201 (expiration 5/31/2025). Approximately 2.2 million vials have been distributed nationwide.
The recall was initiated because the affected lots cannot be assured to meet the sterility requirements mandatory for injectable pharmaceutical products. Sterility is a critical quality attribute for injectable medications to ensure patient safety.
The recalled product
- Product
- Nafcillin for Injection, USP, 1 gram per vial, Rx only, Mfd. for SAGENT Pharmaceuticals, Schaumburg, IL 60195. NDC: 25021-139-10
- Manufacturer
- Sagent Pharmaceuticals Inc
- Category
- Drug — Antibiotic Injection
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot: NFG101
- EXP: 1/31/2024
- Lot: NFG102
- EXP: 9/30/2024
- Lot: NFG201
- 5/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27